PCAB 20 mg is a medication containing Vonoprazan, a potassium-competitive acid blocker (P-CAB) developed by Renata Limited. Unlike traditional proton pump inhibitors (PPIs), Vonoprazan does not require activation by acidic pH and is metabolized by the CYP3A4 enzyme, offering consistent acid suppression regardless of food intake. It is particularly effective in treating acid-related gastrointestinal disorders.